Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform : a real-world two-center experience in Greece
BACKGROUND: Limited information exists on epidermal growth factor receptor (EGFR) molecular epidemiology in Greece. Next-generation sequencing (NGS) is the recommended method for EGFR genotyping in NSCLC. The Idylla Biocartis platform is a fully automated system for actionable EGFR mutation detection.
RESEARCH DESIGN AND METHODS: We describe the prevalence of EGFR mutations in NSCLC patients in two high-volume clinical centers in Greece and compare key methods used for their determination. Eight hundred and fifty-seven FFPE samples from NSCLC patients were tested for EGFR mutations at University of Crete (UoC; n = 324) and at Evangelismos Hospital, Athens (Evangelismos; n = 503).
RESULTS: The prevalence of EGFR mutations was 11.1% in the whole cohort (11.5% in non-squamous). The detection rate was 11.0% by NGS, 9.8% by Sanger and 11.3% by Idylla for the whole cohort (12.0% in non-squamous). The agreement between Idylla and Sanger was 93.2%. A targetable EGFR mutation was detected in 10.0% using tissue NGS alone, and in 16.0% using concurrent Idylla ctEGFR testing.
CONCLUSION: The frequency of EGFR mutations was as expected for a Caucasian population. The Idylla EGFR test performance is comparable to reference methods and with a shorter TAT. Adding a concurrent plasma Idylla test to tissue NGS testing increases the detection rate of EGFR mutations in NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert review of molecular diagnostics - 24(2024), 1-2 vom: 21. Jan., Seite 89-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michaelidou, Kleita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cartridge-based PCR system |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 22.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737159.2024.2303320 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366837699 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366837699 | ||
| 003 | DE-627 | ||
| 005 | 20240222232309.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737159.2024.2303320 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1302.xml |
| 035 | |a (DE-627)NLM366837699 | ||
| 035 | |a (NLM)38193169 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Michaelidou, Kleita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform |b a real-world two-center experience in Greece |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Limited information exists on epidermal growth factor receptor (EGFR) molecular epidemiology in Greece. Next-generation sequencing (NGS) is the recommended method for EGFR genotyping in NSCLC. The Idylla Biocartis platform is a fully automated system for actionable EGFR mutation detection | ||
| 520 | |a RESEARCH DESIGN AND METHODS: We describe the prevalence of EGFR mutations in NSCLC patients in two high-volume clinical centers in Greece and compare key methods used for their determination. Eight hundred and fifty-seven FFPE samples from NSCLC patients were tested for EGFR mutations at University of Crete (UoC; n = 324) and at Evangelismos Hospital, Athens (Evangelismos; n = 503) | ||
| 520 | |a RESULTS: The prevalence of EGFR mutations was 11.1% in the whole cohort (11.5% in non-squamous). The detection rate was 11.0% by NGS, 9.8% by Sanger and 11.3% by Idylla for the whole cohort (12.0% in non-squamous). The agreement between Idylla and Sanger was 93.2%. A targetable EGFR mutation was detected in 10.0% using tissue NGS alone, and in 16.0% using concurrent Idylla ctEGFR testing | ||
| 520 | |a CONCLUSION: The frequency of EGFR mutations was as expected for a Caucasian population. The Idylla EGFR test performance is comparable to reference methods and with a shorter TAT. Adding a concurrent plasma Idylla test to tissue NGS testing increases the detection rate of EGFR mutations in NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cartridge-based PCR system | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Sanger sequencing | |
| 650 | 4 | |a circulating cell-free DNA | |
| 650 | 4 | |a epidermal growth factor receptor mutations | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Karniadakis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Pantelaion, Varvara |e verfasserin |4 aut | |
| 700 | 1 | |a Koutoulaki, Chara |e verfasserin |4 aut | |
| 700 | 1 | |a Boukla, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Folinas, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Dimaras, Pantelis |e verfasserin |4 aut | |
| 700 | 1 | |a Papadaki, Maria A |e verfasserin |4 aut | |
| 700 | 1 | |a Koutsopoulos, Anastasios V |e verfasserin |4 aut | |
| 700 | 1 | |a Mavroudis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Vourlakou, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Mavridis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Agelaki, Sofia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of molecular diagnostics |d 2001 |g 24(2024), 1-2 vom: 21. Jan., Seite 89-98 |w (DE-627)NLM117852775 |x 1744-8352 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1-2 |g day:21 |g month:01 |g pages:89-98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737159.2024.2303320 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1-2 |b 21 |c 01 |h 89-98 | ||